Print  |  Close

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies


Active: No
Cancer Type: Leukemia
Neuroblastoma
Non-Hodgkin Lymphoma
NCT ID: NCT03236857
Trial Phases: Phase I Protocol IDs: M13-833 (primary)
NCI-2017-02027
2017-000439-14
Eligibility: 0 - 25 Years, Male and Female Study Type: Treatment
Study Sponsor: Abbvie
NCI Full Details: http://clinicaltrials.gov/show/NCT03236857

Summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of
venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended
Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and
young adult participants with relapsed or refractory malignancies.

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.